Contacts: Investor Inquiries: Shrinal Inamdar Director, Investor Relations (604) 678-1388 ir@zymeworks.com investors@zymeworks.com Media Inquiries: Diana Papove Senior Director, Corporate Communications (604) 678-1388 ir@zymeworks.com media@zymeworks.com Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by dif ...

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provid ...

Zymeworks Inc. (NASDAQ:ZYME) Q1 2024 Earnings Call Transcript May 2, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - city Ivy Wang - Jefferies Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator. Welcome to Zymeworks First Quarter 2024 Results Conference Call and Webcast. ...

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results • Reported $420.5 million in cash resources as of March 31, 2024,which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 • Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) by our partner, Jazz Pharmac ...

| --- | --- | --- | --- | --- | |-------|-----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | 4Q & FY 2023 Results | | | | | | Conference Call and Webcast | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities E ...

Zymeworks Inc. (NASDAQ:ZYME) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer Ken Galbraith - Chair and CEO Conference Call Participants Stephen Willey - Stifel Ivy Wang - Jefferies Yigal Nochomovitz - Citigroup Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator. Welcome to Zymework ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission file number: 001-41535 _________________________ ZYMEWOR ...

| --- | --- | --- | --- | --- | |-------|-----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | Third Quarter 2023 Results | | | | | | Conference Call and Webcast | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E o ...

Zymeworks Inc. (NASDAQ:ZYME) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Shrinal Inamdar – Director-Investor Relations Chris Astle – Senior Vice President and Chief Financial Officer Paul Moore – Chief Scientific Officer Ken Galbraith – Chair and Chief Executive Officer Conference Call Participants Jonathan Miller – Evercore Ashiq Mubarack – Citi Charles Zhu – Guggenheim Securities Ivy Wang – Jefferies Stephen Willey – Stifel Brian Cheng – JPMorgan Operator Good day, an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 _____________________ ...